Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7085256 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2827903 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2733841 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL25300764 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2734708 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL25299017 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL3344018 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL1286332 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL16721005 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL9754723 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155575-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2020-05-21 | — | — | US | claimed |
| US-20190269700-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2019-09-05 | — | — | US | claimed |
| US-20180078568-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2018-03-22 | — | — | US | claimed |
| US-20160184324-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2016-06-30 | — | — | US | claimed |
| US-20200155575-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20190269700-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20180104257-A1 | (17-ß)-3-Oxoandrost-4-En-17-Yl Undecanoate Compositions and Methods of Their Preparation and Use | LIPOCINE INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180078568-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3185873-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | Lipocine Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20160193225-A1 | (17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE | LIPOCINE INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160184324-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2016033536-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033611-A1 | (17-β)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE | LIPOCINE INC. (US) | 2016-03-03 | — | — | WO | disclosed |